zolucatetide — Topline data
Q4 2026
Expect to present more mature clinical data from the ongoing Phase 1/2 study in desmoid tumors during the fourth quarter of 2026Source filing
PBLS biotech catalysts & pipeline
PARABILIS MEDICINES INC · Data as of 2026-09-08
Upcoming catalysts
zolucatetide — FDA meeting
Q4 2026
Expect to engage with the U.S. Food and Drug Administration (FDA) during the fourth quarter of 2026 to discuss and align on the planned registrational Phase 3 trialSource filing
zolucatetide — Topline data
Q1 2027
Anticipate disclosing additional FAP data in the first quarter of 2027Source filing
zolucatetide — Topline data
H1 2027
Expect to share clinical data from additional patients in the first half of 2027 for ACP, a locally aggressive tumor arising near the pituitary gland associated with significant lifelong morbidity and no approved drug therapies, with a conservatively estimated 15-year prevalence of approximately 5,000 to 9,000 patients in the U.S.Source filing
zolucatetide — Conference presentation
Oct 23–Oct 27
Abstract accepted for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 (Oct. 23-27, Madrid), with a plan to share clinical data from the February data cut from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patientsSource filing